Acupressure Versus Transcutaneous Electrical Nerve Stimulation on Pain and Quality of Life Intradialysis

May 10, 2024 updated by: Alaa Mohamed El-Moatasem Mohamed, Cairo University

Hemodialysis patients have a high prevalence of pain, mainly musculoskeletal and intra dialytic pain. A high prevalence of pain was also observed in the upper and lower limbs and the trunk. In addition, severe functional interference of pain in the ability to walk was associated with pain in the upper Limb. These results indicate that pain in hemodialysis patients is limiting and disabling (Dos Santos et al., 2021).

Acupressure increases relaxation, relieves pain, and reduces anxiety and depression, especially in the elderly. It is relatively inexpensive, safe, non-invasive, and easy to use and is performed by hands, elbows. by applying pressure to specific areas of the body so muscle spasms are relieved, blood circulation and vital energy are improved (Bastani et al.,2022).

Strong non-painful TENS within or close to the site of pain produces clinically important reductions in the intensity of pain during or immediately after treatment. With no reports of serious adverse events. TENS as an adjunct to core treatment or immediate short-term relief of pain, irrespective of diagnosis. Patients should be advised to tailor TENS Treatment according to their individual needs (Johnson et al., 2022).

Study Overview

Detailed Description

Sixty patients will be randomly assigned into two equal groups (n=30):

  1. Group A (30 patients) will receive Acupressure three times per week for eight weeks.
  2. Group B (30 patients) will receive TENS three times per week for eight weeks.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt, 11432
        • Cairo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • • Sixty patients with renal failure stage 5 undergoing hemodialysis sessions at least six months ago up to 2 years.

    • Participants with lower limb pain and brief pain inventory (BPI) pain score between 7 and 10 points.
    • Body mass index ranges from 25 to 29.9.
    • Their ages range from 50-60 years old.
    • All patients will be under full medical control.
    • Patients will be free from lower limb dialysis grafting.
    • Hemoglobin level more than 10 mg\dl.

Exclusion Criteria:

  • Skin disease such as dermatitis, stitches and wound.
  • Active infection, autoimmune diseases and malignancy.
  • Severe cardiac diseases.
  • Severe chest diseases.
  • Patients with cardiac pacemaker.
  • Epilepsy.
  • Using another integrative treatment method during the study.
  • Uncontrolled diabetes.
  • Deep vein thrombosis.
  • Lumber disc prolapses affect lower limb.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Acupressure
The acupressure points will be determined, patients are informed that they will feel soft vibrations and pain during acupressure application. Patients are advised that it is sufficient for them to feel the vibrations of the acupressure device slightly. It be felt first symmetrically right knee, right leg, left knee, left leg Patients will receive acupressure 24 sessions three times a week for eight weeks. After application the patient will be asked about the severity of pain half an hour after administration (Çevik & Taşcı, 2020).
Acupressure is effective on anxiety and depression management. acupressure therapy at K1, ST36, and SP6 acupoints significantly reduced anxiety & depression in patients with ESRD.
Active Comparator: Transcutaneous electrical nerve stimulation

• Placement electrodes applied on the painful area lower leg.

Settings:

  • Intensity up to patient tolerance.
  • Duration 30min.
TENS lead to meaningful reduction of pain in patients suffering from difficult to treat phantom limb pain. This treatment has a high success rate and is associated with high satisfaction rates and no reported adverse events. The suggested duration of treatment is at least 30 minutes and may be extended up to 45 minutes. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extra segmental analgesia. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extrasegmental analgesia. (Vathakul et al., 2022).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain pressure algometry:
Time Frame: Pain pressure algometry:will be measured at baseline, and it will be measured again after eight weeks
Pain pressure algometry: Device to measure the intensity of painful stimuli objectively
Pain pressure algometry:will be measured at baseline, and it will be measured again after eight weeks
The Brief Pain Inventory (BPI):
Time Frame: The Brief Pain Inventory (BPI): will be measured at baseline, and it will be measured again after eight weeks
The Brief Pain Inventory (BPI): Is a multidimensional pain assessment tool used to evaluate pain severity and pain interference. The BPI has been translated and validity estimated across multiple languages and patient populations for clinical and research settings.
The Brief Pain Inventory (BPI): will be measured at baseline, and it will be measured again after eight weeks
Short form -36 questionnaire (KDQoL SF-36):
Time Frame: Short form -36 questionnaire (KDQoL SF-36):will be measured at baseline, and it will be measured again after eight weeks
Short form -36 questionnaire (KDQoL SF-36): Is generic measure of health that has also been used widely in trials in hemodialysis patients for the objective measure quality of life
Short form -36 questionnaire (KDQoL SF-36):will be measured at baseline, and it will be measured again after eight weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incremental shuttle walking test (ISWT):
Time Frame: The incremental shuttle walking test (ISWT):will be measured at baseline, and it will be measured again after eight weeks
The incremental shuttle walking test (ISWT):Is an important marker of aerobic capacity in patients on renal dialysis
The incremental shuttle walking test (ISWT):will be measured at baseline, and it will be measured again after eight weeks
Patient health questionnaire PHQ-9:
Time Frame: Patient health questionnaire PHQ-9:will be measured at baseline, and it will be measured again after eight weeks
Patient health questionnaire PHQ-9: Is a nine-item questionnaire designed to screen depression in primary care and other medical settings
Patient health questionnaire PHQ-9:will be measured at baseline, and it will be measured again after eight weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hany Obaya, assistant professor, giza, Egypt, 12511

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 28, 2023

Primary Completion (Actual)

January 30, 2024

Study Completion (Actual)

April 22, 2024

Study Registration Dates

First Submitted

October 19, 2023

First Submitted That Met QC Criteria

October 19, 2023

First Posted (Actual)

October 24, 2023

Study Record Updates

Last Update Posted (Actual)

May 13, 2024

Last Update Submitted That Met QC Criteria

May 10, 2024

Last Verified

December 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • P.T.REC/012/004482

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hemodialysis Complication

Clinical Trials on Acupressure

Subscribe